Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Tema Cardiovascular and Metabolic ETF (HRTS)

Tema Cardiovascular and Metabolic ETF (HRTS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
27.44 +0.07 (+0.26%) 04/22/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 27.44 unch (unch) 16:15 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
27.44
Day High
27.75
Open 27.46
Previous Close 27.37 27.37
Volume 2,400 2,400
Avg Vol 10,375 10,375
Stochastic %K 56.60% 56.60%
Weighted Alpha -16.47 -16.47
5-Day Change -0.48 (-1.72%) -0.48 (-1.72%)
52-Week Range 25.32 - 36.03 25.32 - 36.03
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Tema ETFs
  • Assets Under Management 53,233,600
  • Shares Outstanding, K 1,940
  • 60-Month Beta N/A
  • Price/Earnings ttm N/A
  • Annual Dividend & Yield 0.47 (1.71%)
  • Most Recent Dividend 0.469 on 12/11/24
  • Management Fee 0.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.32 +8.38%
on 04/09/25
Period Open: 29.98
30.47 -9.94%
on 03/25/25
-2.54 (-8.47%)
since 03/21/25
3-Month
25.32 +8.38%
on 04/09/25
Period Open: 29.33
30.95 -11.34%
on 02/21/25
-1.89 (-6.44%)
since 01/22/25
52-Week
25.32 +8.38%
on 04/09/25
Period Open: 31.12
36.03 -23.84%
on 07/16/24
-3.68 (-11.83%)
since 04/22/24

Most Recent Stories

More News
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

TCAF : 30.41 (+2.29%)
ASND : 159.13 (-1.25%)
IBB : 120.43 (+2.72%)
HRTS : 27.44 (+0.26%)
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

VXF : 162.43 (+2.71%)
KROS : 13.89 (-2.87%)
HRTS : 27.44 (+0.26%)
XBI : 77.64 (+2.82%)
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR

For Immediate ReleaseChicago, IL – October 17, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 59.91 (+2.71%)
LLY : 827.54 (+1.16%)
HRTS : 27.44 (+0.26%)
PPH : 84.77 (+1.84%)
THNR : 20.61 (+2.21%)
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global...

NVO : 59.91 (+2.71%)
LLY : 827.54 (+1.16%)
HRTS : 27.44 (+0.26%)
PPH : 84.77 (+1.84%)
THNR : 20.61 (+2.21%)
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

NVO : 59.91 (+2.71%)
OZEM : 23.33 (+2.10%)
LLY : 827.54 (+1.16%)
HRTS : 27.44 (+0.26%)
RHHBY : 38.9800 (+0.46%)
THNR : 20.61 (+2.21%)
Not Sure Which Weight Loss Stock to Buy? Invest in This ETF

Many healthcare companies have been eagerly developing new weight loss drugs in an effort to cash in ...

VKTX : 25.48 (+7.42%)
LLY : 827.54 (+1.16%)
HRTS : 27.44 (+0.26%)
Don’t Know Which Weight-Loss Stock Will Be the Biggest Winner? Invest in This ETF Instead

There’s a lot of excitement in the weight-loss industry these days. Between Ozempic, Wegovy, Mounjaro, ...

NVO : 59.91 (+2.71%)
HRTS : 27.44 (+0.26%)
LLY : 827.54 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The Tema Cardiovascular and Metabolic ETF seeks to provide long-term growth of capital by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

3rd Resistance Point 27.96
2nd Resistance Point 27.85
1st Resistance Point 27.65
Last Price 27.44
1st Support Level 27.34
2nd Support Level 27.23
3rd Support Level 27.03

See More

52-Week High 36.03
Fibonacci 61.8% 31.94
Fibonacci 50% 30.67
Fibonacci 38.2% 29.41
Last Price 27.44
52-Week Low 25.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro